Prelude Therapeutics files Form 3 for CMO Morris

Prelude Therapeutics Inc filed an initial Form 3 for Chief Medical Officer Charles Q. Morris.

Rhea-AI Filing Summary

Prelude Therapeutics Inc filed an initial Form 3 for Chief Medical Officer Charles Q. Morris. This filing identifies him as an officer and subject to insider reporting rules but, in this excerpt, shows no reported transactions or holdings data.

Key Figures

Buy transactions: 0 transactions Sell transactions: 0 transactions Net buy/sell direction: neutral

3 metrics

Buy transactions 0 transactions Form 3 transaction summary for Charles Q. Morris

Sell transactions 0 transactions Form 3 transaction summary for Charles Q. Morris

Net buy/sell direction neutral Form 3 transaction summary for Charles Q. Morris

Key Terms

Form 3, Chief Medical Officer, netBuySellDirection

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Medical Officer financial

""officer_title": "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

netBuySellDirection financial

""netBuySellDirection": "neutral""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Prelude Therapeutics (PRLD) Form 3 for Charles Q. Morris show?

It documents that Charles Q. Morris is an officer of Prelude Therapeutics and serves as Chief Medical Officer. The excerpted data show no reported buy, sell, acquire, or dispose transactions in company securities at the time of this filing.

Does the PRLD Form 3 for Charles Q. Morris report any stock purchases or sales?

No transactions are reported in the excerpted Form 3 data. The transaction summary shows zero buys, zero sells, zero derivative exercises, and no gifts or tax-withholding events associated with Charles Q. Morris at the time of this filing.

What role does Charles Q. Morris hold at Prelude Therapeutics (PRLD)?

Charles Q. Morris is identified as an officer of Prelude Therapeutics, holding the title of Chief Medical Officer. This role subjects him to insider reporting requirements, including filing Forms 3, 4, and 5 regarding his beneficial ownership and reportable transactions.

What is the purpose of a Form 3 filing for Prelude Therapeutics insiders?

A Form 3 serves as an initial statement of beneficial ownership for company insiders. For Prelude Therapeutics, it records when an officer, director, or significant holder becomes subject to reporting, along with any reportable holdings or transactions included in the filing data.

What does the transaction summary in the PRLD Form 3 indicate?

The transaction summary shows zero counts for buys, sells, exercises, gifts, tax withholding, and restructurings. Net buy-sell direction is listed as neutral, indicating no reportable transaction activity for Charles Q. Morris in the excerpted information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/15/2026 - 04:19 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Morris Charles Q

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Bryant D. Lim, Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)